Search research articles
Contact Us
Filters
Showing results (11-20 of 97) with videos related to
Page
of 10
Sort By:
Circulation
|
July 5, 2017
Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"
Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie
|
September 27, 2013
Development and preliminary validation of a Function IndeX for Trauma (FIX-IT)
Mohit Bhandari, Scott M Wasserman, Nicole Yurgin, et al.
Circulation
|
September 10, 2013
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
Evan A Stein, Narimon Honarpour, Scott M Wasserman, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 26, 2014
Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study
Atsushi Hirayama, Narimon Honarpour, Masayuki Yoshida, et al.
Echocardiography (Mount Kisco, N.Y.)
|
March 9, 2002
Acquired left ventricular-right atrial communication: Gerbode-type defect
Scott M Wasserman, James I Fann, J Edwin Atwood, et al.
Circulation
|
November 7, 2012
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
Frederick Raal, Rob Scott, Ransi Somaratne, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 9, 2018
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
Mita Kuchimanchi, Anita Grover, Maurice G Emery, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 9, 2018
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
Dick C Chan, Gerald F Watts, Ransi Somaratne, et al.
The Journal of Biological Chemistry
|
July 6, 2004
A novel secreted, cell-surface glycoprotein containing multiple epidermal growth factor-like repeats and one CUB domain is highly expressed in primary osteoblasts and bones
Bo-Tsung Wu, Yueh-Hsing Su, Ming-Tzu Tsai, et al.
Circulation Research
|
August 1, 2015
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study
Dirk J Blom, C Stephen Djedjos, Maria Laura Monsalvo, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 97) with videos related to
Sort By:
Page
of 10
Circulation
|
July 5, 2017
Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"
Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie
|
September 27, 2013
Development and preliminary validation of a Function IndeX for Trauma (FIX-IT)
Mohit Bhandari, Scott M Wasserman, Nicole Yurgin, et al.
Circulation
|
September 10, 2013
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
Evan A Stein, Narimon Honarpour, Scott M Wasserman, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 26, 2014
Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study
Atsushi Hirayama, Narimon Honarpour, Masayuki Yoshida, et al.
Echocardiography (Mount Kisco, N.Y.)
|
March 9, 2002
Acquired left ventricular-right atrial communication: Gerbode-type defect
Scott M Wasserman, James I Fann, J Edwin Atwood, et al.
Circulation
|
November 7, 2012
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
Frederick Raal, Rob Scott, Ransi Somaratne, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
May 9, 2018
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
Mita Kuchimanchi, Anita Grover, Maurice G Emery, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
June 9, 2018
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
Dick C Chan, Gerald F Watts, Ransi Somaratne, et al.
The Journal of Biological Chemistry
|
July 6, 2004
A novel secreted, cell-surface glycoprotein containing multiple epidermal growth factor-like repeats and one CUB domain is highly expressed in primary osteoblasts and bones
Bo-Tsung Wu, Yueh-Hsing Su, Ming-Tzu Tsai, et al.
Circulation Research
|
August 1, 2015
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study
Dirk J Blom, C Stephen Djedjos, Maria Laura Monsalvo, et al.
Page
of 10